Despite the slew of data coming out of conferences across the US and Europe during the last two weeks, June 3 - 17, the IPO market has seen no action. That doesn't mean the US biotech window is closed – one of the highest valued IPOs in 2016 has officially been put in the works.
High-profile biotech Kadmon Corp. LLC filed a prospectus with the Securities and Exchange Commission (SEC) on June 10 declaring...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

